|
[1] SOUTO PA,MARCOTEGUI AR,ORBEA L,et al. Hepatic encephalopathy:Ever closer to its big bang[J]. World J Gastroenterol,2016,22(42):9251-9256.
|
|
[2] CAI JX,LOU HL. Sarcopenia[J/CD]. Electr J of Metab Nutrit Cancer,2019,6(1):135-143.(in Chinese)蔡君香，楼慧玲．肌肉减少症[J/CD]．肿瘤代谢与营养电子杂志，2019,6(1):135-143.
|
|
[3] CRUZ-JENTOFT AJ,BAHAT G,BAUER J,et al. Sarcopenia:Revised European consensus on definition and diagnosis[J]. Age Ageing,2019,48(1):16-31.
|
|
[4] CAO P,YAO J,ZHU N,et al. Sarcopenia as an assessment of nutritional status and its risk factors in patients with hepatic cirrhosis[J]. Chin Remed Clin,2017,17(12):1737-1740.(in Chinese)曹平，姚佳，朱娜，等．肌肉减少症评价肝硬化患者营养状况及其影响因素[J]．中国药物与临床，2017,17(12):1737-1739.
|
|
[5] QI Q,WU BW,FEI XY. Research progress of influencing factors of cancer-related sarcopenia[J]. Chin Gen Pract,2018,21(15):1769-1774.(in Chinese)戚倩，吴蓓雯，费晓燕．肿瘤相关性肌肉减少症影响因素的研究进展[J]．中国全科医学，2018,21(15):1769-1774.
|
|
[6] KIM HY,JANG JW. Sarcopenia in the prognosis of cirrhosis:Going beyond the MELD score[J]. World J Gastroenterol,2015,21(25):7637-7647.
|
|
[7] LI YQ,ZHANG AQ,CAO P,et al. Predictive value of the third lumbar skeletal muscle mass index on prognosis of patients with cirrhosis and ascites[J]. Chin J Hepatol,2019,27(10):806-808.(in Chinese)李玉琴，张爱青，曹平，等．第三腰椎骨骼肌质量指数对肝硬化腹水患者预后的预测价值[J]．中华肝脏病杂志，2019,27(10):806-808.
|
|
[8] MITSIOPOULOS N,BAUMGARTNER RN,HEYMSFIELD SB,et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography[J]. J Appl Physiol(1985),1998,85(1):115-122.
|
|
[9] ZHUANG W,ZHANG MM. Definition and diagnostic criteria of myopenia[J/CD]. Electr J of Metab Nutrit Cancer,2014,1(3):1-4.(in Chinese)庄文，张明鸣．肌肉减少症的定义和诊断标准[J/CD]．肿瘤代谢与营养电子杂志，2014,1(3):1-4.
|
|
[10] LU YM,CHEN QP. The diagnosis and therapy of sarcopenia[J/CD]. Chin J Clinicians(Electronic Edition),2014,8(24):4454-4457.(in Chinese)卢艳敏，陈强谱．肌肉减少症的诊断及治疗[J/CD]．中华临床医师杂志(电子版)，2014,8(24):4454-4457.
|
|
[11] MARCELL TJ. Sarcopenia:Causes,consequences,and preventions[J]. J Gerontol A Biol Sci Med Sci,2003,58(10):m911-m916.
|
|
[12] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol,2018,34(10):2076-2089.(in Chinese)中华医学会肝病分学会．肝硬化肝性脑病诊疗指南[J]．临床肝胆病杂志，2018,34(10):2076-2089.
|
|
[13] PATIDAR KR,BAJAJ JS. Covert and overt hepatic encephalopathy:Diagnosis and management[J]. Clin Gastroenterol Hepatol,2015,13(12):2048-2061.
|
|
[14] TANG SH,CHEN H,HAN GH. Association between gut microbiota and hepatic encephalopathy in patients with liver addiction[J]. J Clin Hepatol,2019,35(5):1109-1113.(in Chinese)汤世豪，陈辉，韩国宏．肠道菌群与肝硬化肝性脑病的关系[J]．临床肝胆病杂志，2019,35(5):1109-1113.
|
|
[15] ELWIR S,RAHIMI RS. Hepatic encephalopathy:An update on the pathophysiology and therapeutic options[J]. J Clin Transl Hepatol,2017,5(2):142-151.
|
|
[16] REN PP,XIE Q. Treatment and prevention of hepatic encephalopathy targeting muscles[J]. Chin Hepatol,2017,22(3):194-195.(in Chinese)任佩佩，谢青．以肌肉为靶点的肝性脑病治疗和预防[J]．肝脏，2017,22(3):194-195.
|
|
[17] ROMEIRO FG,AUGUSTI L. Nutritional assessment in cirrhotic patients with hepatic encephalopathy[J]. World J Hepatol,2015,7(30):2940-2954.
|
|
[18] CHANG KV,CHEN JD,WU WT,et al. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis[J]. J Formos Med Assoc,2019,118(4):833-842.
|
|
[19] CHEN HL,WANG Q. Pathogenesis and treatment for alcoholic liver disease with sarcopenia:A review[J]. Chin J Mult Organ Dis Elderly,2018,17(10):784-788.(in Chinese)陈海亮，王琦．酒精性肝病肌肉减少症:发病机制与治疗进展[J]．中华老年多器官疾病杂志，2018,17(10):784-788.
|
|
[20] HAN F,HAN T,LIANG J. Assessment and clinical management of sarcopenia in patients with liver grading[J]. J Clin Hepatol,2019,35(4):891-894.(in Chinese)韩芳，韩涛，梁静．肝硬化患者肌少症的评估与临床管理[J]．临床肝胆病杂志，2019,35(4):891-894.
|
|
[21] SWAMINATHAN M,ELLUL MA,CROSS TJ. Hepatic encephalopathy:Current challenges and future prospects[J]. Hepat Med,2018,10:1-11.
|
|
[22] YE T,LONG H,LIN CX. Nutrition and exercise management status in patients with cirrhosis[J]. Youjiang Med J,2016,44(2):233-236.(in Chinese)叶婷，龙华，林承雄．肝硬化患者的营养和运动管理状况[J]．右江医学，2016,44(2):233-236.
|
|
[23] TAJIRI K,SHIMIZU Y. Branched-chain amino acids in liver diseases[J]. Transl Gastroenterol Hepatol,2018,3:47.
|
|
[24] YU R,SHI Q,LIU L,et al. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease:A meta-analysis[J]. BMC Gastroenterol,2018,18(1):51.
|
|
[25] DASARATHY S,MERLI M. Sarcopenia from mechanism to diagnosis and treatment in liver disease[J]. J Hepatol,2016,65(6):1232-1244.
|
|
[26] BAJAJ JS. The role of microbiota in hepatic encephalopathy[J]. Gut Microbes,2014,5(3):397-403.
|
|
[27] VIDOT H,BOWEN DG,CAREY S,et al. Aggressive nutrition intervention reduces ascites and frequency of paracentesis in malnourished patients with cirrhosis and ascites[J]. JGH Open,2017,1(3):92-97.
|
|
[28] OHASHI K,ISHIKAWA T,HOSHI A,et al. Relationship between sarcopenia and both physical activity and lifestyle in patients with chronic liver disease[J]. J Clin Med Res,2018,10(12):920-927.
|
DownLoad: